Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes

NCT02464033 is registered in ClinicalTrials.gov with Johnny Ludvigsson as lead sponsor.

NCT NCT02464033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02464033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes
Lead sponsor
Johnny Ludvigsson
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
February 25, 2019
Enrollment
20 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1